Aprogen Medicines Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 890.45 million compared to KRW 339.42 million a year ago. Net loss was KRW 25,326.98 million compared to KRW 25,174.74 million a year ago.

Basic loss per share from continuing operations was KRW 108 compared to KRW 145 a year ago. Diluted loss per share from continuing operations was KRW 108 compared to KRW 145 a year ago. Basic loss per share was KRW 108 compared to KRW 145 a year ago.